File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus

TitleBiomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus
Authors
Issue Date2015
Citation
Molecular Cancer Therapeutics, 2015, v. 14, p. 1048-1056 How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/212509
ISSN
2023 Impact Factor: 5.3
2023 SCImago Journal Rankings: 2.270
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiu, Y-
dc.contributor.authorStarr, M-
dc.contributor.authorBrady, J-
dc.contributor.authorRushing, C-
dc.contributor.authorBulusu, A-
dc.contributor.authorPang, HMH-
dc.contributor.authorHoneycutt, W-
dc.contributor.authorAmara, A-
dc.contributor.authorAltomare, I-
dc.contributor.authorUronis, H-
dc.date.accessioned2015-07-21T02:37:56Z-
dc.date.available2015-07-21T02:37:56Z-
dc.date.issued2015-
dc.identifier.citationMolecular Cancer Therapeutics, 2015, v. 14, p. 1048-1056-
dc.identifier.issn1535-7163-
dc.identifier.urihttp://hdl.handle.net/10722/212509-
dc.languageeng-
dc.relation.ispartofMolecular Cancer Therapeutics-
dc.titleBiomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus-
dc.typeArticle-
dc.identifier.emailPang, HMH: herbpang@hku.hk-
dc.identifier.authorityPang, HMH=rp01857-
dc.identifier.doi10.1158/1535-7163.MCT-14-0923-T-
dc.identifier.pmid25695956-
dc.identifier.scopuseid_2-s2.0-84955670381-
dc.identifier.hkuros244616-
dc.identifier.volume14-
dc.identifier.spage1048-
dc.identifier.epage1056-
dc.identifier.isiWOS:000358052500020-
dc.identifier.issnl1535-7163-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats